• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Pro Medicus’ 7-Year, Usage-Based St. Luke’s Deal Require Action From ASX:PME Investors?

    Simply Wall St·08/14/2026 11:23:11
    语音播报
    • In August 2026, Pro Medicus announced it had secured a 7-year, A$23,000,000 contract with St. Luke’s Health System to deploy its cloud-based Visage 7 enterprise imaging platform across three US states, covering both Visage 7 Viewer and Visage 7 Workflow.
    • An interesting element of this deal is its transaction-based licensing model, which ties Pro Medicus’s revenue to actual imaging usage and creates scope for scalable income over the contract term.
    • We’ll now explore how this long-term, usage-based St. Luke’s contract could influence Pro Medicus’s existing investment narrative built around US hospital growth.

    AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Pro Medicus Investment Narrative Recap

    To own Pro Medicus, you need to believe its premium imaging platform can keep winning large US health systems on long contracts that translate into growing transaction revenue. The St. Luke’s A$23,000,000, 7 year deal reinforces that US hospital thesis but does not materially change the near term risk that any slowdown in US imaging volumes or tighter hospital budgets could pressure pricing and premium multiples.

    Against this backdrop, the February 2026 half year result, with revenue of A$128.94 million and net income of A$171.22 million, is the most relevant recent announcement. It reminded investors that expectations for growth and margins are already very high, so new contracts like St. Luke’s are being assessed not just on size, but on how reliably they may convert the existing backlog into future earnings.

    However, investors should also be aware that if US imaging budgets tighten or buyers prioritise cheaper alternatives...

    Read the full narrative on Pro Medicus (it's free!)

    Pro Medicus' narrative projects A$453.7 million revenue and A$259.5 million earnings by 2029. This requires 23.5% yearly revenue growth and an A$24.8 million earnings increase from A$234.7 million today.

    Uncover how Pro Medicus' forecasts yield a A$190.74 fair value, a 7% upside to its current price.

    Exploring Other Perspectives

    ASX:PME 1-Year Stock Price Chart
    ASX:PME 1-Year Stock Price Chart

    Some of the lowest ranked analysts were already cautious, assuming earnings of about A$223.7 million by 2029 and lower margins, so a contract like St. Luke’s might eventually push those more pessimistic views to adjust, but it also highlights how differently you and other investors can interpret the same A$400.9 million revenue path.

    Explore 10 other fair value estimates on Pro Medicus - why the stock might be worth as much as 12% more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Seeking Other Investments?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.